Carl R Lupica

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4969310/publications.pdf

Version: 2024-02-01

103 papers	7,408 citations	44069 48 h-index	56724 83 g-index
115 all docs	115 docs citations	115 times ranked	7807 citing authors

#	Article	IF	Citations
1	Reversing anterior insular cortex neuronal hypoexcitability attenuates compulsive behavior in adolescent rats. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2121247119.	7.1	3
2	Muscarinic Acetylcholine M₂ Receptors Regulate Lateral Habenula Neuron Activity and Control Cocaine Seeking Behavior. Journal of Neuroscience, 2022, 42, 5552-5563.	3.6	5
3	Impairment of Synaptic Plasticity by Cannabis, Î”⁹-THC, and Synthetic Cannabinoids. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a039743.	6.2	10
4	Effects of Withdrawal from Cocaine Self-Administration on Rat Orbitofrontal Cortex Parvalbumin Neurons ExpressingCre recombinase: Sex-Dependent Changes in Neuronal Function and Unaltered Serotonin Signaling. ENeuro, 2021, 8, ENEURO.0017-21.2021.	1.9	9
5	Lateral habenula cannabinoid CB1 receptor involvement in drug-associated impulsive behavior. Neuropharmacology, 2021, 192, 108604.	4.1	10
6	Striatal Rgs4 regulates feeding and susceptibility to diet-induced obesity. Molecular Psychiatry, 2020, 25, 2058-2069.	7.9	14
7	Altered Corticolimbic Control of the Nucleus Accumbens by Long-term Î”9-Tetrahydrocannabinol Exposure. Biological Psychiatry, 2020, 87, 619-631.	1.3	20
8	Positive Allosteric Modulation of the 5-HT_{1A} Receptor by Indole-Based Synthetic Cannabinoids Abused by Humans. ACS Chemical Neuroscience, 2020, 11, 1400-1405.	3.5	19
9	(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice. Neurobiology of Disease, 2019, 130, 104528.	4.4	33
10	Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats. Neuron, 2019, 102, 105-119.e8.	8.1	62
11	Novel and Potent Dopamine D₂ Receptor Go-Protein Biased Agonists. ACS Pharmacology and Translational Science, 2019, 2, 52-65.	4.9	43
12	Cocaine-induced endocannabinoid signaling mediated by sigma-1 receptors and extracellular vesicle secretion. ELife, 2019, 8, .	6.0	36
13	Novel sumanirole bivalent analogues as potent dopamine D2 receptor Goâ€protein biased agonists. FASEB Journal, 2019, 33, 667.11.	0.5	0
14	Phasic Dopamine Signals in the Nucleus Accumbens that Cause Active Avoidance Require Endocannabinoid Mobilization in the Midbrain. Current Biology, 2018, 28, 1392-1404.e5.	3.9	64
15	Optogenetic silencing of a corticotropin-releasing factor pathway from the central amygdala to the bed nucleus of the stria terminalis disrupts sustained fear. Molecular Psychiatry, 2018, 23, 914-922.	7.9	72
16	Cannabinoid disruption of learning mechanisms involved in reward processing. Learning and Memory, 2018, 25, 435-445.	1.3	12
17	Cocaine Regulates Endocannabinoids-Containing Extracellular Vesicles Release in Ventral Tegmental Area via Sigma-1 Receptor and ADP-Ribosylation Factor 6 Pathway. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-79.	0.0	0
18	Enduring Loss of Serotonergic Control of Orbitofrontal Cortex Function Following Contingent and Noncontingent Cocaine Exposure. Cerebral Cortex, 2017, 27, 5463-5476.	2.9	6

#	Article	IF	Citations
19	Disruption of hippocampal synaptic transmission and longâ€term potentiation by psychoactive synthetic cannabinoid â€˜Spiceâ€™ compounds: comparison with Î”⁹â€tetrahydrocannabinol. Addiction Biology, 2017, 22, 390-399.	2.6	36
20	Cannabinoids as hippocampal network administrators. Neuropharmacology, 2017, 124, 25-37.	4.1	46
21	Lateral Habenula Involvement in Impulsive Cocaine Seeking. Neuropsychopharmacology, 2017, 42, 1103-1112.	5.4	35
22	CYP3A5 Mediates Effects of Cocaine on Human Neocorticogenesis: Studies using an In Vitro 3D Self-Organized hPSC Model with a Single Cortex-Like Unit. Neuropsychopharmacology, 2017, 42, 774-784.	5.4	68
23	Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry. ACS Chemical Neuroscience, 2016, 7, 700-709.	3.5	37
24	Dopaminergic and glutamatergic microdomains in a subset of rodent mesoaccumbens axons. Nature Neuroscience, 2015, 18, 386-392.	14.8	222
25	Norepinephrine Activates Dopamine D₄Receptors in the Rat Lateral Habenula. Journal of Neuroscience, 2015, 35, 3460-3469.	3.6	62
26	Cocaine-Induced Endocannabinoid Mobilization in the Ventral Tegmental Area. Cell Reports, 2015, 12, 1997-2008.	6.4	77
27	Pharmacological Characterization of a Dopamine Transporter Ligand That Functions as a Cocaine Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 106-115.	2.5	17
28	Orbitofrontal activation restores insight lost after cocaine use. Nature Neuroscience, 2014, 17, 1092-1099.	14.8	57
29	Anin vitromodel of human neocortical development using pluripotent stem cells: cocaine-induced cytoarchitectural alterations. DMM Disease Models and Mechanisms, 2014, 7, 1397-405.	2.4	7
30	Correction to â€œ2-Isoxazol-3-Phenyltropane Derivatives of Cocaine: Molecular and Atypical System Effects at the Dopamine Transporterâ€• Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 534-534.	2.5	1
31	A glutamatergic reward input from the dorsal raphe to ventral tegmental area dopamine neurons. Nature Communications, 2014, 5, 5390.	12.8	158
32	Single rodent mesohabenular axons release glutamate and GABA. Nature Neuroscience, 2014, 17, 1543-1551.	14.8	290
33	2-Isoxazol-3-Phenyltropane Derivatives of Cocaine: Molecular and Atypical System Effects at the Dopamine Transporter. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 297-309.	2.5	28
34	Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 24-27.	4.8	49
35	New technologies for examining the role of neuronal ensembles in drug addiction and fear. Nature Reviews Neuroscience, 2013, 14, 743-754.	10.2	215
36	Synaptic Targets of Â9-Tetrahydrocannabinol in the Central Nervous System. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a012237-a012237.	6.2	49

#	Article	IF	Citations
37	Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive â€˜Bath Saltsâ€™ Products. Neuropsychopharmacology, 2013, 38, 552-562.	5.4	361
38	Cocaine Drives Aversive Conditioning via Delayed Activation of Dopamine-Responsive Habenular and Midbrain Pathways. Journal of Neuroscience, 2013, 33, 7501-7512.	3.6	175
39	Dopamine D₄Receptor Excitation of Lateral Habenula Neurons via Multiple Cellular Mechanisms. Journal of Neuroscience, 2013, 33, 16853-16864.	3.6	56
40	PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice. Brain, 2012, 135, 2736-2749.	7.6	39
41	Silent synapses in selectively activated nucleus accumbens neurons following cocaine sensitization. Nature Neuroscience, 2012, 15, 1556-1562.	14.8	85
42	Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Human Molecular Genetics, 2012, 21, 1078-1089.	2.9	69
43	Attenuated response to methamphetamine sensitization and deficits in motor learning and memory after selective deletion of Â-catenin in dopamine neurons. Learning and Memory, 2012, 19, 341-350.	1.3	15
44	Medial Prefrontal Cortex Neuronal Activation and Synaptic Alterations after Stress-Induced Reinstatement of Palatable Food Seeking: A Study Using c-fos-GFP Transgenic Female Rats. Journal of Neuroscience, 2012, 32, 8480-8490.	3.6	60
45	Blockade of Î²-cell KATP channels by the endocannabinoid, 2-arachidonoylglycerol. Biochemical and Biophysical Research Communications, 2012, 423, 13-18.	2.1	12
46	Altered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbuminâ€containing interneurons in the medial prefrontal cortex of cannabinoidâ€1 (CB1) receptor knockout mice. Journal of Comparative Neurology, 2012, 520, 4013-4031.	1.6	35
47	Linking Context with Reward: A Functional Circuit from Hippocampal CA3 to Ventral Tegmental Area. Science, 2011, 333, 353-357.	12.6	343
48	Decreased parvalbumin immunoreactivity in the cortex and striatum of mice lacking the CB1 receptor. Synapse, 2011, 65, 827-831.	1.2	18
49	Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB Journal, 2011, 25, 1333-1344.	0.5	112
50	Cannabinoid-1 receptor gene deletion has a compartment-specific affect on the dendritic and axonal availability of Î¼-opioid receptors and on dopamine axons in the mouse nucleus accumbens. Synapse, 2010, 64, 886-897.	1.2	15
51	NMDA Receptors on Non-Dopaminergic Neurons in the VTA Support Cocaine Sensitization. PLoS ONE, 2010, 5, e12141.	2.5	39
52	Afferent-Specific AMPA Receptor Subunit Composition and Regulation of Synaptic Plasticity in Midbrain Dopamine Neurons by Abused Drugs. Journal of Neuroscience, 2010, 30, 7900-7909.	3.6	59
53	Î”9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology, 2010, 59, 121-127.	4.1	66
54	Control of Cannabinoid CB₁Receptor Function on Glutamate Axon Terminals by Endogenous Adenosine Acting at A₁Receptors. Journal of Neuroscience, 2010, 30, 545-555.	3.6	91

#	Article	IF	Citations
55	Nogo receptor 1 regulates formation of lasting memories. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20476-20481.	7.1	76
56	Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology, 2009, 204, 1-11.	3.1	68
57	Properties of distinct ventral tegmental area synapses activated via pedunculopontine or ventral tegmental area stimulation in vitro. Journal of Physiology, 2009, 587, 1233-1247.	2.9	38
58	Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity. European Journal of Medicinal Chemistry, 2009, 44, 593-608.	5.5	16
59	A Novel Combination of Factors, Termed SPIE, which Promotes Dopaminergic Neuron Differentiation from Human Embryonic Stem Cells. PLoS ONE, 2009, 4, e6606.	2.5	79
60	MPTPâ€induced deficits in striatal synaptic plasticity are prevented by glial cell lineâ€derived neurotrophic factor expressed via an adenoâ€associated viral vector. FASEB Journal, 2008, 22, 261-275.	0.5	51
61	Gene Expression Profile of Neuronal Progenitor Cells Derived from hESCs: Activation of Chromosome 11p15.5 and Comparison to Human Dopaminergic Neurons. PLoS ONE, 2008, 3, e1422.	2.5	36
62	Dopaminergic neurons derived from BG01V2, a variant of human embryonic stem cell line BG01. Restorative Neurology and Neuroscience, 2008, 26, 447-58.	0.7	7
63	Opposing actions of chronic Â9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learning and Memory, 2007, 14, 63-74.	1.3	126
64	The Endocannabinoid Anandamide Inhibits the Function of Î±4Î²2 Nicotinic Acetylcholine Receptors. Molecular Pharmacology, 2007, 72, 1024-1032.	2.3	57
65	Visualizing Cannabinoid Effects Using Brain Slice Imaging and Electrophysiological Approaches. , 2006, 123, 105-112.		1
66	Queer Currents, Steady Rhythms, and Drunken DA Neurons. Focus on â€œHyperpolarization-Activated Cation Current (Ih) Is an Ethanol Target in Midbrain Dopamine Neurons of Miceâ€. Journal of Neurophysiology, 2006, 95, 585-586.	1.8	9
67	Man-Made Marijuana. , 2005, , .		1
68	Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. European Journal of Neuroscience, 2005, 22, 2387-2391.	2.6	50
69	Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology, 2005, 48, 1105-1116.	4.1	216
70	Independent Presynaptic and Postsynaptic Mechanisms Regulate Endocannabinoid Signaling at Multiple Synapses in the Ventral Tegmental Area. Journal of Neuroscience, 2004, 24, 11070-11078.	3.6	201
71	Differential Effects of Endogenous and Synthetic Cannabinoids on Î±₇-Nicotinic Acetylcholine Receptor-Mediated Responses in Xenopus Oocytes. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1152-1160.	2.5	65
72	Marijuana and cannabinoid regulation of brain reward circuits. British Journal of Pharmacology, 2004, 143, 227-234.	5.4	227

#	Article	IF	Citations
73	The solubilizing detergents, Tween 80 and Triton X-100 non-competitively inhibit Î±7-nicotinic acetylcholine receptor function in Xenopus oocytes. Journal of Neuroscience Methods, 2004, 137, 167-173.	2.5	35
74	Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus. European Journal of Neuroscience, 2003, 18, 524-534.	2.6	76
75	It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends in Neurosciences, 2003, 26, 184-192.	8.6	443
76	Functional Tolerance and Blockade of Long-Term Depression at Synapses in the Nucleus Accumbens after Chronic Cannabinoid Exposure. Journal of Neuroscience, 2003, 23, 4815-4820.	3.6	183
77	Contribution of the Hyperpolarization-Activated Current (I _h) to Membrane Potential and GABA Release in Hippocampal Interneurons. Journal of Neurophysiology, 2001, 86, 261-268.	1.8	148
78	Direct Actions of Cannabinoids on Synaptic Transmission in the Nucleus Accumbens: A Comparison With Opioids. Journal of Neurophysiology, 2001, 85, 72-83.	1.8	182
79	Mechanisms of Cannabinoid Inhibition of GABA_ASynaptic Transmission in the Hippocampus. Journal of Neuroscience, 2000, 20, 2470-2479.	3.6	384
80	Opioid Receptor Subtype Expression Defines Morphologically Distinct Classes of Hippocampal Interneurons. Journal of Neuroscience, 1999, 19, 85-95.	3.6	88
81	Voltage-dependency of the dopamine transporter in the rat substantia nigra. Neuroscience Letters, 1999, 260, 105-108.	2.1	34
82	Antagonists of the Receptor-G Protein Interface Block Gi-coupled Signal Transduction. Journal of Biological Chemistry, 1998, 273, 14912-14919.	3.4	92
83	Opioid Inhibition of Hippocampal Interneurons via Modulation of Potassium and Hyperpolarization-Activated Cation (I_h) Currents. Journal of Neuroscience, 1998, 18, 7084-7098.	3.6	95
84	Cholecystokinin Increases GABA Release by Inhibiting a Resting K⁺Conductance in Hippocampal Interneurons. Journal of Neuroscience, 1997, 17, 4994-5003.	3.6	85
85	Neuropeptide FF inhibition of morphine effects in the rat hippocampus. Brain Research, 1997, 750, 81-86.	2.2	21
86	Delta and mu enkephalins inhibit spontaneous GABA-mediated IPSCs via a cyclic AMP-independent mechanism in the rat hippocampus. Journal of Neuroscience, 1995, 15, 737-749.	3.6	108
87	Characterization of Histaminergic H3 Receptors in Intraocular Tuberomammillary Transplants Containing Histaminergic Neurons. Experimental Neurology, 1995, 136, 12-21.	4.1	2
88	Functional localization of mu and delta enkephalin-mediated inhibition of GABA release to nerve terminals in the hippocampus. Regulatory Peptides, 1994, 53, S177-S178.	1.9	1
89	Delta opioid mediated-increases in hippocampal excitability occur via activation of a delta1-like receptor. Regulatory Peptides, 1994, 54, 167-168.	1.9	3
90	Cholecystokinin (CCK) inhibits excitation of pyramidal neurons by non-peptide, but not peptide, opioid agonists in the rat hippocampus. Regulatory Peptides, 1994, 54, 195-196.	1.9	0

#	Article	IF	Citations
91	Activity-dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. Journal of Neuroscience, 1993, 13, 3439-3447.	3.6	183
92	Adenosine Modulation of Glutamate-Mediated Synaptic Transmission in the Hippocampus. , 1993, , 104-126.		4
93	Presynaptic inhibition of excitatory synaptic transmission by adenosine in rat hippocampus: analysis of unitary EPSP variance measured by whole- cell recording. Journal of Neuroscience, 1992, 12, 3753-3764.	3.6	125
94	Dissociation of Î¼ and Î´ opioid receptor-mediated reductions in evoked and spontaneous synaptic inhibition in the rat hippocampus in vitro. Brain Research, 1992, 593, 226-238.	2.2	52
95	Chronic theophylline treatment in vivo increases high affinity adenosine A1 receptor binding and sensitivity to exogenous adenosine in the in vitro hippocampal slice. Brain Research, 1991, 542, 55-62.	2.2	21
96	Differential effects of mu- and delta-receptor selective opioid agonists on feedforward and feedback GABAergic inhibition in hippocampal brain slices. Synapse, 1991, 8, 237-248.	1.2	50
97	Chronic theophylline treatment increases adenosine A1, but not A2, receptor binding in the rat brain: An autoradiographic study. Synapse, 1991, 9, 95-102.	1.2	44
98	Adenosine involvement in postictal events in amygdala-kindled rats. Epilepsy Research, 1990, 6, 171-179.	1.6	50
99	Release of endogenous adenosine does not mediate electrophysiological responses to morphine in the hippocampus in vitro. Neuropharmacology, 1990, 29, 1131-1139.	4.1	4
100	Adenosine Involvement in Kindled Seizures. Advances in Behavioral Biology, 1990, , 423-440.	0.2	15
101	Atropine slows olfactory bulb kindling while diminished cholinergic innervation does not. Brain Research Bulletin, 1988, 20, 203-209.	3.0	10
102	Effects of local anesthesia on persistence of peripherally induced postural asymmetries in rats.. Behavioral Neuroscience, 1983, 97, 921-927.	1.2	12
103	Effects of manipulating stimulation intensity and duration on fixation of a peripherally-induced spinal reflex alteration in rats. Physiology and Behavior, 1982, 29, 1039-1044.	2.1	7